PU.1 cooperates with IRF4 and IRF8 to suppress pre-B-cell leukemia

Leukemia

Volumn 30, Issue 6, 2016, Pages 1375-1387

  Pang, S H M ^a,b   Minnich, M ^c   Gangatirkar, P ^a,b   Zheng, Z ^a   Ebert, A ^c   Song, G ^d   Dickins, R A ^a,b,e   Corcoran, L M ^a,b   Mullighan, C G ^d   Busslinger, M ^c   Huntington, N D ^a,b   Nutt, S L ^a,b   Carotta, S ^a,b,f  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c RESEARCH INSTITUTE OF MOLECULAR PATHOLOGY   (Austria)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^e MONASH UNIVERSITY   (Australia)

^f BOEHRINGER INGELHEIM RCV GMBH AND CO KG   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON CONSENSUS SEQUENCE BINDING PROTEIN; INTERFERON REGULATORY FACTOR 4; INTERLEUKIN 7; TRANSCRIPTION FACTOR PU 1; INTERFERON REGULATORY FACTOR; INTERFERON REGULATORY FACTOR-4; ONCOPROTEIN; PROTO-ONCOGENE PROTEIN SPI-1; TRANSACTIVATOR PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B CELL LEUKEMIA; B LYMPHOCYTE DIFFERENTIATION; BINDING SITE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; ECTOPIC EXPRESSION; ENHANCER REGION; HUMAN; MOUSE; NONHUMAN; PRE B LYMPHOCYTE; PRIORITY JOURNAL; ANIMAL; B LYMPHOCYTE; CYTOLOGY; GENE EXPRESSION REGULATION; GENETICS; KNOCKOUT MOUSE; LYMPHOPOIESIS; PHYSIOLOGY; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

ANIMALS; B-LYMPHOCYTES; GENE EXPRESSION REGULATION; INTERFERON REGULATORY FACTORS; LYMPHOPOIESIS; MICE; MICE, KNOCKOUT; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTO-ONCOGENE PROTEINS; TRANS-ACTIVATORS;

EID: 84960361941     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2016.27     Document Type: Article

References (59)

1. Pongubala JM, Nagulapalli S, Klemsz MJ, McKercher SR, Maki RA, Atchison ML. PU1 recruits a second nuclear factor to a site important for immunoglobulin kappa 3' enhancer activity. Mol Cell Biol 1992; 12: 368-378.
2. Kanno Y, Levi B-Z, Tamura T, Ozato K. Immune cell-specific amplification of interferon signaling by the IRF-4/8-PU.1 complex. J Interferon Cytokine Res 2005; 25: 770-779.
3. Eisenbeis CF, Singh H, Storb U. Pip, a novel IRF family member, is a lymphoidspecific, PU.1-dependent transcriptional activator. Genes Dev 1995; 9: 1377-1387.
4. Eisenbeis CF, Singh H, Storb U. PU.1 is a component of a multiprotein complex which binds an essential site in the murine immunoglobulin lambda 2-4 enhancer. Mol Cell Biol 1993; 13: 6452-6461.
5. Brass AL, Zhu AQ, Singh H. Assembly requirements of PU.1-Pip (IRF-4) activator complexes: inhibiting function in vivo using fused dimers. EMBO J 1999; 18: 977-991.
6. Brass AL, Kehrli E, Eisenbeis CF, Storb U, Singh H. Pip, a lymphoid-restricted IRF, contains a regulatory domain that is important for autoinhibition and ternary complex formation with the Ets factor PU.1. Genes Dev 1996; 10: 2335-2347.
7. Ochiai K, Maienschein-Cline M, Simonetti G, Chen J, Rosenthal R, Brink R et al. Transcriptional regulation of germinal center B and plasma cell fates by dynamical control of IRF4. Immunity 2013; 38: 918-929.
8. Heinz S, Benner C, Spann N, Bertolino E, Lin YC, Laslo P et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol Cell 2010; 38: 576-589.
9. Scott EW, Simon MC, Anastasi J, Singh H. Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages. Science 1994; 265: 1573-1577.
10. Scott EW, Fisher RC, Olson MC, Kehrli EW, Simon MC, Singh H. PU.1 functions in a cell-autonomous manner to control the differentiation of multipotential lymphoid-myeloid progenitors. Immunity 1997; 6: 437-447.
11. Polli M, Dakic A, Light A, Wu L, Tarlinton D, Nutt S. The development of functional B lymphocytes in conditional PU.1 knock-out mice. Blood 2005; 106: 2083-2090.
12. Ye M, Ermakova O, Graf T. PU.1 is not strictly required for B cell development and its absence induces a B-2 to B-1 cell switch. J Exp Med 2005; 202: 1411-1422.
13. Sokalski KM, Li SKH, Welch I, Cadieux-Pitre H-AT, Gruca MR, Dekoter RP. Deletion of genes encoding PU.1 and Spi-B in B cells impairs differentiation and induces pre-B cell acute lymphoblastic leukemia. Blood 2011; 118: 1-33.
14. Johnson K, Hashimshony T, Sawai CM, Pongubala JM, Skok JA, Aifantis I et al. Regulation of immunoglobulin light-chain recombination by the transcription factor IRF-4 and the attenuation of interleukin-7 signaling. Immunity 2008; 28: 335-345.
15. Lu R, Medina KL, Lancki DW, Singh H. IRF-4,8 orchestrate the pre-B-to-B transition in lymphocyte development. Genes Dev 2003; 17: 1703-1708.
16. Ma S, Pathak S, Trinh L, Lu R. Interferon regulatory factors 4 and 8 induce the expression of Ikaros and Aiolos to down-regulate pre-B-cell receptor and promote cell-cycle withdrawal in pre-B-cell development. Blood 2008; 111: 1396-1403.
17. Ma S, Turetsky A, Trinh L, Lu R. IFN regulatory factor 4 and 8 promote Ig light chain kappa locus activation in pre-B cell development. J Immunol 2006; 177: 7898-7904.
18. Cook WD, McCaw BJ, Herring C, John DL, Foote SJ, Nutt SL et al. PU.1 is a suppressor of myeloid leukemia, inactivated in mice by gene deletion and mutation of its DNA binding domain. Blood 2004; 104: 3437-3444.
19. Holtschke T, Löhler J, Kanno Y, Fehr T, Giese N, Rosenbauer F et al. Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell 1996; 87: 307-317.
20. Metcalf D, Dakic A, Mifsud S, Di Rago L, Wu L, Nutt S. Inactivation of PU.1 in adult mice leads to the development of myeloid leukemia. Proc Natl Acad Sci USA 2006; 103: 1486-1491.
21. Rosenbauer F, Koschmieder S, Steidl U, Tenen DG. Effect of transcription-factor concentrations on leukemic stem cells. Blood 2005; 106: 1519-1524.
22. Rosenbauer F, Wagner K, Kutok JL, Iwasaki H, Le Beau MM, Okuno Y et al. Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1. Nat Genet 2004; 36: 624-630.
23. Scheller M, Schonheit J, Zimmermann K, Leser U, Rosenbauer F, Leutz A. Cross talk between Wnt/beta-catenin and Irf8 in leukemia progression and drug resistance. J Exp Med 2013; 210: 2239-2256.
24. Steidl U, Steidl C, Ebralidze A, Chapuy B, Han HJ, Will B et al. A distal single nucleotide polymorphism alters long-range regulation of the PU.1 gene in acute myeloid leukemia. J Clin Invest 2007; 117: 2611-2620.
25. Mullighan CG, Zhang J, Kasper LH, Lerach S, Payne-Turner D, Phillips LA et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature 2011; 471: 235-239.
26. Zhang J, Mullighan CG, Harvey RC, Wu G, Chen X, Edmonson M et al. Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 2011; 118: 3080-3087.
27. Bouamar H, Abbas S, Lin AP, Wang L, Jiang D, Holder KN et al. A capturesequencing strategy identifies IRF8, EBF1, and APRIL as novel IGH fusion partners in B-cell lymphoma. Blood 2013; 122: 726-733.
28. Niebuhr B, Kriebitzsch N, Fischer M, Behrens K, Gunther T, Alawi M et al. Runx1 is essential at two stages of early murine B-cell development. Blood 2013; 122: 413-423.
29. Shukla V, Ma S, Hardy RR, Joshi SS, Lu R. A role for IRF4 in the development of CLL. Blood 2013; 122: 2848-2855.
30. Shaffer AL, Emre NC, Romesser PB, Staudt LM. IRF4: Immunity. Malignancy! Therapy? Clin Cancer Res 2009; 15: 2954-2961.
31. Adamaki M, Lambrou GI, Athanasiadou A, Tzanoudaki M, Vlahopoulos S, Moschovi M. Implication of IRF4 aberrant gene expression in the acute leukemias of childhood. PLoS One 2013; 8: e72326.
32. Acquaviva J, Chen X, Ren R. IRF-4 functions as a tumor suppressor in early B-cell development. Blood 2008; 112: 3798-3806.
33. Pathak S, Ma S, Trinh L, Eudy J, Wagner KU, Joshi SS et al. IRF4 is a suppressor of c-Myc induced B cell leukemia. PLoS One 2011; 6: e22628.
34. Jo SH, Schatz JH, Acquaviva J, Singh H, Ren R. Cooperation between deficiencies of IRF-4 and IRF-8 promotes both myeloid and lymphoid tumorigenesis. Blood 2010; 116: 2759-2767.
35. Xu LS, Sokalski KM, Hotke K, Christie DA, Zarnett O, Piskorz J et al. Regulation of B cell linker protein transcription by PU.1 and Spi-B in murine B cell acute lymphoblastic leukemia. J Immunol 2012; 189: 3347-3354.
36. Carotta S, Willis SN, Hasbold J, Inouye M, Pang SH, Emslie D et al. The transcription factors IRF8 and PU.1 negatively regulate plasma cell differentiation. J Exp Med 2014; 211: 2169-2181.
37. Dakic A, Metcalf D, Di Rago L, Mifsud S, Wu L, Nutt SL. PU.1 regulates the commitment of adult hematopoietic progenitors and restricts granulopoiesis. J Exp Med 2005; 201: 1487-1502.
38. Mittrücker HW, Matsuyama T, Grossman A, Kündig TM, Potter J, Shahinian A et al. Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function. Science 1997; 275: 540-543.
39. Hobeika E, Thiemann S, Storch B, Jumaa H, Nielsen PJ, Pelanda R et al. Testing gene function early in the B cell lineage in mb1-cre mice. Proc Natl Acad Sci USA 2006; 103: 13789-13794.
40. DeKoter RP, Lee HJ, Singh H. PU.1 regulates expression of the interleukin-7 receptor in lymphoid progenitors. Immunity 2002; 16: 297-309.
41. Anderson KL, Nelson SL, Perkin HB, Smith KA, Klemsz MJ, Torbett BE. PU.1 is a lineage-specific regulator of tyrosine phosphatase CD45. J Biol Chem 2001; 276: 7637-7642.
42. Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 2007; 446: 758-764.
43. Decker T, Pasca di Magliano M, McManus S, Sun Q, Bonifer C, Tagoh H et al. Stepwise activation of enhancer and promoter regions of the B cell commitment gene Pax5 in early lymphopoiesis. Immunity 2009; 30: 508-520.
44. Minegishi Y, Rohrer J, Coustan-Smith E, Lederman HM, Pappu R, Campana D et al. An essential role for BLNK in human B cell development. Science 1999; 286: 1954-1957.
45. Pappu R, Cheng AM, Li B, Gong Q, Chiu C, Griffin N et al. Requirement for B cell linker protein (BLNK) in B cell development. Science 1999; 286: 1949-1954.
46. Jumaa H, Wollscheid B, Mitterer M, Wienands J, Reth M, Nielsen PJ. Abnormal development and function of B lymphocytes in mice deficient for the signaling adaptor protein SLP-65. Immunity 1999; 11: 547-554.
47. Jumaa H, Bossaller L, Portugal K, Storch B, Lotz M, Flemming A et al. Deficiency of the adaptor SLP-65 in pre-B-cell acute lymphoblastic leukaemia. Nature 2003; 423: 452-456.
48. Wang JH, Nichogiannopoulou A, Wu L, Sun L, Sharpe AH, Bigby M et al. Selective defects in the development of the fetal and adult lymphoid system in mice with an Ikaros null mutation. Immunity 1996; 5: 537-549.
49. Ma S, Pathak S, Mandal M, Trinh L, Clark MR, Lu R. Ikaros and Aiolos inhibit pre-B-cell proliferation by directly suppressing c-Myc expression. Mol Cell Biol 2010; 30: 4149-4158.
50. Heizmann B, Kastner P, Chan S. Ikaros is absolutely required for pre-B cell differentiation by attenuating IL-7 signals. J Exp Med 2013; 210: 2823-2832.
51. Joshi I, Yoshida T, Jena N, Qi X, Zhang J, Van Etten RA et al. Loss of Ikaros DNAbinding function confers integrin-dependent survival on pre-B cells and progression to acute lymphoblastic leukemia. Nat Immunol 2014; 15: 294-304.
52. Schwickert TA, Tagoh H, Gultekin S, Dakic A, Axelsson E, Minnich M et al. Stagespecific control of early B cell development by the transcription factor Ikaros. Nat Immunol 2014; 15: 283-293.
53. Mullighan C, Downing J. Ikaros and acute leukemia. Leuk Lymphoma 2008; 49: 847-849.
54. Mullighan CG, Su X, Zhang J, Radtke I, Phillips LAA, Miller CB et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 2009; 360: 470-480.
55. DeKoter R, Singh H. Regulation of B lymphocyte and macrophage development by graded expression of PU.1. Science 2000; 288: 1439-1441.
56. Rosenbauer F, Owens BM, Yu L, Tumang JR, Steidl U, Kutok JL et al. Lymphoid cell growth and transformation are suppressed by a key regulatory element of the gene encoding PU.1. Nat Genet 2006; 38: 27-37.
57. Schebesta A, McManus S, Salvagiotto G, Delogu A, Busslinger GA, Busslinger M. Transcription factor Pax5 activates the chromatin of key genes involved in B cell signaling, adhesion, migration, and immune function. Immunity 2007; 27: 49-63.
58. Greig KT, de Graaf CA, Murphy JM, Carpinelli MR, Pang SH, Frampton J et al. Critical roles for c-Myb in lymphoid priming and early B-cell development. Blood 2010; 115: 2796-2805.
59. Ferreiros-Vidal I, Carroll T, Taylor B, Terry A, Liang Z, Bruno L et al. Genome-wide identification of Ikaros targets elucidates its contribution to mouse B-cell lineage specification and pre-B-cell differentiation. Blood 2013; 121: 1769-1782.